Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor The Kuderer/Peppercorn Article Reviewed

被引：0
|
作者：
Goetz, Matthew P. [1 ,2 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Pharmacol, Rochester, MN USA
来源：
ONCOLOGY-NEW YORK | 2009年 / 23卷 / 14期
关键词：
BREAST-CANCER; WOMEN; THERAPY; ADHERENCE; BIOTRANSFORMATION; ANASTROZOLE; METABOLISM; GENOTYPE; OUTCOMES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1233 / 1236
页数：3
相关论文
共 50 条
  • [31] The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
    Ferraldeschi, Roberta
    Newman, William G.
    PHARMACEUTICALS, 2010, 3 (04) : 1122 - 1138
  • [32] CYP2D6 and Tamoxifen: Awaiting the Denouement Reply
    Rae, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4590 - 4591
  • [33] CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
    Jansen, Laura E.
    Teft, Wendy A.
    Rose, Rhiannon V.
    Lizotte, Daniel J.
    Kim, Richard B.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 701 - 708
  • [34] Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
    Hertz, Daniel L.
    Deal, Allison
    Ibrahim, Joseph G.
    Walko, Christine M.
    Weck, Karen E.
    Anderson, Steven
    Magrinat, Gustav
    Olajide, Oludamilola
    Moore, Susan
    Raab, Rachel
    Carrizosa, Daniel R.
    Corso, Steven
    Schwartz, Garry
    Graham, Mark
    Peppercorn, Jeffrey M.
    Jones, David R.
    Desta, Zeruesenay
    Flockhart, David A.
    Evans, James P.
    McLeod, Howard L.
    Carey, Lisa A.
    Irvin, William J., Jr.
    ONCOLOGIST, 2016, 21 (07): : 795 - 803
  • [35] CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
    Balakrishnar, Bavanthi
    Menzies, Alexander M.
    Ali, Sayed Sahanawaz
    Yeap, Shang Heng
    Gao, Bo
    Liddle, Chris
    Coulter, Sally
    Provan, Pamela
    Gebski, Val
    Hui, Rina
    Kefford, Richard
    Wilcken, Nicholas
    Balleine, Rosemary L.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer
    Casali da Rocha, Jose Claudio
    Nardin, Jeanine M.
    Schroth, Werner
    Almeida, Thais A.
    Muerdter, Thomas
    Picolotto, Solange
    Vendramini, Evelyn C. L.
    Hoppe, Reiner
    Kogin, Jenifer P.
    Miqueleto, Diandra
    Moraes, Silvia D. R.
    Schwab, Matthias
    Pecoits-Filho, Roberto F.
    Brauch, Hiltrud
    CANCER RESEARCH, 2020, 80 (04)
  • [37] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    F. L. Opdam
    V. O. Dezentje
    J. den Hartigh
    A. S. Modak
    R. Vree
    E. Batman
    C. H. Smorenburg
    J. W. R. Nortier
    H. Gelderblom
    H.-J. Guchelaar
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 593 - 601
  • [38] CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
    Laura E. Jansen
    Wendy A. Teft
    Rhiannon V. Rose
    Daniel J. Lizotte
    Richard B. Kim
    Breast Cancer Research and Treatment, 2018, 171 : 701 - 708
  • [39] The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer
    Nardin, Jeanine Marie
    Schroth, Werner
    Almeida, Thais Abreu
    Muerdter, Thomas
    Picolotto, Solane
    Lima Vendramini, Evelyn Castillo
    Hoppe, Reiner
    Kogin, Jenifer Primon
    Miqueleto, Diandra
    Robaskievicz de Moraes, Silvia Dark
    Schwab, Matthias
    Pecoits-Filho, Roberto Flavio
    Brauch, Hiltrud
    Casali-da-Rocha, Jose Claudio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02): : 284 - 292
  • [40] The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
    Opdam, F. L.
    Dezentje, V. O.
    den Hartigh, J.
    Modak, A. S.
    Vree, R.
    Batman, E.
    Smorenburg, C. H.
    Nortier, J. W. R.
    Gelderblom, H.
    Guchelaar, H. -J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 593 - 601
12345